GLOBAL PULMONARY DRUG DELIVERY MARKET FORECAST 2019-2028

  • You are here:
  • Home
  • Reports
  • GLOBAL PULMONARY DRUG DELIVERY MARKET FORECAST 2019-2028

GLOBAL PULMONARY DRUG DELIVERY MARKET FORECAST 2019-2028

The global pulmonary drug delivery market is projected to register a CAGR of 5.06%, generating a $65073 million revenue by 2028. The base year considered for the market study is 2018, and the forecast years are from 2019 to 2028. There has been a considerable increase in patient population due to the rising incidence of chronic respiratory diseases. As a result, the demand for pulmonary drug delivery systems is projected to accelerate over the forecast period.

GLOBAL PULMONARY DRUG DELIVERY MARKET FORECAST 2019-2028

Global Pulmonary Drug Delivery Market by Application (Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Cystic Fibrosis, Other Applications) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-commerce) by End-user (Hospitals & Clinics, Homecare) by Product (Metered Dose Inhalers, Dry Powder Inhalers, Nebulizer (Pneumatic Nebulizer (Breath Actuated Pneumatic Nebulizer, Vented Pneumatic Nebulizer),  Mesh Nebulizer (Vibrating Mesh Nebulizer, Static Mesh Nebulizer), Ultrasonic Nebulizer), Accessories) and by Geography.

Request free sample

The global pulmonary drug delivery market is projected to register a CAGR of 5.06%, generating a $65073 million revenue by 2028. The base year considered for the market study is 2018, and the forecast years are from 2019 to 2028.

There has been a considerable increase in patient population due to the rising incidence of chronic respiratory diseases. As a result, the demand for pulmonary drug delivery systems is projected to accelerate over the forecast period.

global-pulmonary-drug-delivery-market

To know more about this report, request a free sample copy

Key factors propelling the global pulmonary drug delivery market growth:

  • Growing prevalence of respiratory diseases
  • Advancements in technology
  • Rising geriatric population
    • Aging severely affects respiration, as the maximum functioning of the respiratory system begins to decreases gradually. For instance, the effectiveness of lung defense mechanisms declines as individuals age.
    • Older people are at a higher risk of developing respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), among others.

Major restraining factors of the global pulmonary drug delivery market:

  • Stringent regulations and patent expiry
    • While developing a new drug or a medical device like pulmonary drug delivery systems, the manufacturing companies must consider its integrity, sterility, and functionality.
    • The Food and Drug Administration (FDA) has laid down stringent guidelines regarding the same.
    • Numerous blockbuster drugs have lost patent protection in recent years, with several more expected to lose theirs in the upcoming years. Thus, the loss of the drug or the delivery system’s exclusivity can negatively impact the manufacturing company.
  • Increasing drug recalls and drug failures
  • Side effects and risk associated with the drugs

The report scope of the global pulmonary drug delivery market growth includes the segmentation analysis of product, application, distribution channel, and end-user. These segments are further classified to provide a detailed analysis of the studied market.

Market by Application:

  • Asthma
    • Asthma is projected to be the dominating segment, under the application category.
    • Effective inhalation therapy using metered dose inhalers (MDIs) and dry powder inhalers (DPIs) are the cornerstones of asthma management.
    • Thus, owing to a large number of patients within the segment, the demand, and usage of pulmonary drug delivery systems like MDIs and DPIs for treating asthma are increasing. Consequently, this reinforces the segment’s growth.
  • Chronic Obstructive Pulmonary Disease
    • Chronic obstructive pulmonary disease is the fastest-growing application.
    • The majority of the drugs available in the market for treating the chronic respiratory disease are delivered using inhalers and nebulizers.
    • Additionally, favorable reimbursement policies for treating COPD are also a significant factor contributing to the segment’s growth.
  • Cystic Fibrosis
  • Allergic Rhinitis
  • Others

Geographically, the global pulmonary drug delivery market has been segmented based on four major regions, which includes:

  • North America: The United States and Canada
    • North America is set to be the dominating region in the global pulmonary drug delivery market.
    • The increasing prevalence of asthma and chronic obstructive pulmonary disease (COPD) is expected to drive the region’s market growth. According to the National Institutes of Health (NIH), approximately 12 million adults have been diagnosed by COPD in the United States.
    • Moreover, the chronic respiratory condition results in nearly 120,000 deaths, every year. Thus, the increasing incidence of respiratory diseases is a predominant factor attributed to driving the overall market growth, across the forecast period.
  • Europe: The United Kingdom, Germany, Italy, France, Belgium, Russia, Poland, and Rest of Europe
  • Asia Pacific: India, Australia & New Zealand, China, South Korea, Japan, Thailand, Indonesia, Vietnam, and Rest of Asia Pacific
    • The Asia Pacific is anticipated to emerge as the fastest-growing market for pulmonary drug delivery, by the end of the forecast period.
    • The presence of supportive non-government organizations such as the Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI), essentially promotes the Asia Pacific’s market growth. These associations strive to provide information about the fundamental and clinical research on allergy, asthma, and clinical immunology, in addition to high-untapped opportunities.
    • Conversely, as of 2017, there were nearly three million asthmatics in Japan, out of which 7% and 30% had severe and moderate asthma, respectively.
  • Rest of World: Latin America, the Middle East & Africa

The major market players operating in the global pulmonary drug delivery market: 

  • GlaxoSmithKline PLC
  • 3M Company
  • Koninklijke Philips NV
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Others

Key strategies adopted by companies within the global pulmonary drug delivery market:

In July 2020, AstraZeneca entered a new worldwide commercialization and development contract with Daiichi Sankyo Corporation for DS-1062. The company’s exclusive trophoblast cell-surface antigen 2 (TROP2), is a possible modern medicine for treating numerous tumor forms and a focused antibody-drug conjugate (ADC).

Key findings of the global pulmonary drug delivery market:

  • There are initiatives set by public and private organizations to reduce the incidence of respiratory diseases.
  • There is a growing prevalence of COPD and asthma.
  • Retail Pharmacies segment, under the distribution channel category, is expected to witness the fastest growth over the forecast period
  • The metered dose inhalers segment, under the product category, fostered the largest market share in 2019.

 

Frequently Asked Questions & Answers (FAQs):

  • Which country has generated the highest revenue across the global pulmonary drug delivery market?

     A: The United States has generated the highest revenue, within the global pulmonary drug delivery market.

  • How competitive is the global pulmonary drug delivery market?

     A: The market is highly competitive with key players involved in continuous product development and partnership alliances, to aid market penetration.

  • What are the long-term prospects of the global pulmonary drug delivery market?

   A: In the long run, the global pulmonary drug delivery market is anticipated to grow, owing to a substantial increase in the prevalence of respiratory diseases.

  1. RESEARCH SCOPE & METHODOLOGY
    • STUDY OBJECTIVES
    • SCOPE OF STUDY
    • METHODOLOGY
    • ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    • MARKET SIZE & ESTIMATES
    • MARKET OVERVIEW
  3. MARKET DYNAMICS
    • PARENT MARKET ANALYSIS: DRUG DELIVERY MARKET
    • DEVELOPMENT OF DRUG DELIVERY SYSTEM
    • MARKET DEFINITION
    •    KEY DRIVERS
      • GROWING PREVALENCE OF RESPIRATORY DISEASE
      • ADVANCEMENTS IN TECHNOLOGY
      • RISING GERIATRIC POPULATION
    •    KEY RESTRAINTS
      • STRINGENT REGULATION AND PATENT EXPIRY
      • INCREASING DRUG RECALLS AND DRUG FAILURES
      • SIDE EFFECTS AND RISK ASSOCIATED WITH THE DRUGS
  1. KEY ANALYTICS
    •    PORTER’S FIVE FORCE ANALYSIS
      • THREAT OF NEW ENTRY
      • THREAT OF SUBSTITUTION
      • BUYER’S POWER
      • SUPPLIER’S POWER
      • COMPETITIVE RIVALRY
    • REGULATORY FRAMEWORK
    • IMPACT OF COVID-19 ON PULMONARY DRUG DELIVERY MARKET
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
    • KEY INVESTMENT INSIGHTS
  2. MARKET BY APPLICATION
    • ASTHMA
    • CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    • ALLERGIC RHINITIS
    • CYSTIC FIBROSIS
    • OTHER APPLICATIONS
  3. MARKET BY DISTRIBUTION CHANNEL
    • HOSPITAL PHARMACIES
    • RETAIL PHARMACIES
    • E-COMMERCE
  4. MARKET BY END-USER
    • HOSPITALS & CLINICS
    • HOMECARE
  5. MARKET BY PRODUCT
    • METERED DOSE INHALERS
    • DRY POWDER INHALERS
    •    NEBULIZER
      •    PNEUMATIC NEBULIZER
        • BREATH ACTUATED PNEUMATIC NEBULIZER
        • VENTED PNEUMATIC NEBULIZER
      •    MESH NEBULIZER
        • VIBRATING MESH NEBULIZER
        • STATIC MESH NEBULIZER
      • ULTRASONIC NEBULIZER
    • ACCESSORIES
  6. GEOGRAPHICAL ANALYSIS
    •    NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    •    EUROPE
      • GERMANY
      • THE UNITED KINGDOM
      • FRANCE
      • ITALY
      • RUSSIA
      • BELGIUM
      • POLAND
      • REST OF EUROPE
    •    ASIA PACIFIC
      • CHINA
      • JAPAN
      • INDIA
      • AUSTRALIA & NEW ZEALAND
      • SOUTH KOREA
      • THAILAND
      • INDONESIA
      • VIETNAM
      • REST OF ASIA PACIFIC
    •    REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA
  1. COMPANY PROFILES
    • 3M COMPANY
    • ACTELION PHARMACEUTICALS LTD
    • AEROGEN
    • AGILENT TECHNOLOGIES INC
    • ASTRAZENECA PLC
    • BOEHRINGER INGELHEIM GMBH
    • CLEMENT CLARKE INTERNATIONAL
    • GF HEALTH PRODUCTS INC
    • GLAXOSMITHKLINE PLC
    • KONINKLIJKE PHILIPS NV
    • MERCK & CO INC
    • NOVARTIS AG
    • TEVA PHARMACEUTICAL INDUSTRIES LIMITED
    • VECTURA GROUP PLC

TABLE LIST

TABLE 1: MARKET SNAPSHOT – PULMONARY DRUG DELIVERY

TABLE 2: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 3: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY APPLICATION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 4: GLOBAL ASTHMA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 5: GLOBAL ASTHMA MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 6: GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 7: GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 8: GLOBAL ALLERGIC RHINITIS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 9: GLOBAL ALLERGIC RHINITIS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 10: GLOBAL CYSTIC FIBROSIS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 11: GLOBAL CYSTIC FIBROSIS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 12: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 13: GLOBAL OTHER APPLICATIONS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 14: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 15: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 16: GLOBAL HOSPITAL PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 17: GLOBAL HOSPITAL PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 18: GLOBAL RETAIL PHARMACIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 19: GLOBAL RETAIL PHARMACIES MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 20: GLOBAL E-COMMERCE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 21: GLOBAL E-COMMERCE MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 22: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 23: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 24: GLOBAL HOSPITALS & CLINICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 25: GLOBAL HOSPITALS & CLINICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 26: GLOBAL HOMECARE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 27: GLOBAL HOMECARE MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 28: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 29: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY PRODUCT, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 30: GLOBAL METERED DOSE INHALERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 31: GLOBAL METERED DOSE INHALERS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 32: GLOBAL DRY POWDER INHALERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 33: GLOBAL DRY POWDER INHALERS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 34: GLOBAL NEBULIZER MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 35: GLOBAL NEBULIZER MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 36: GLOBAL NEBULIZER MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 37: GLOBAL NEBULIZER MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 38: GLOBAL PNEUMATIC NEBULIZER MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 39: GLOBAL PNEUMATIC NEBULIZER MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 40: GLOBAL PNEUMATIC NEBULIZER MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 41: GLOBAL PNEUMATIC NEBULIZER MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 42: GLOBAL MESH NEBULIZER MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 43: GLOBAL MESH NEBULIZER MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 44: GLOBAL MESH NEBULIZER MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 45: GLOBAL MESH NEBULIZER MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 46: GLOBAL ULTRASONIC NEBULIZER MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 47: GLOBAL ULTRASONIC NEBULIZER MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 48: GLOBAL ACCESSORIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 49: GLOBAL ACCESSORIES MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 50: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 51: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY REGION MARKET, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 52: NORTH AMERICA PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 53: NORTH AMERICA PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 54: EUROPE PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 55: EUROPE PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 56: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 57: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)

TABLE 58: REST OF WORLD PULMONARY DRUG DELIVERY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)

TABLE 59: REST OF WORLD PULMONARY DRUG DELIVERY MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

FIGURE LIST          

FIGURE 1: GLOBAL POPULATION, BY AGE GROUP 2015 & 2020 (IN MILLION)

FIGURE 2: PORTER’S FIVE FORCE ANALYSIS

FIGURE 3: OPPORTUNITY MATRIX

FIGURE 4: VENDOR LANDSCAPE

FIGURE 5: KEY INVESTMENT INSIGHTS

FIGURE 6: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY APPLICATION, IN 2019

FIGURE 7: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY ASTHMA, 2019-2028 (IN $ MILLION)

FIGURE 8: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2019-2028 (IN $ MILLION)

FIGURE 9: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY ALLERGIC RHINITIS, 2019-2028 (IN $ MILLION)

FIGURE 10: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY CYSTIC FIBROSIS, 2019-2028 (IN $ MILLION)

FIGURE 11: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY OTHER APPLICATIONS, 2019-2028 (IN $ MILLION)

FIGURE 12: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL, IN 2019

FIGURE 13: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY HOSPITAL PHARMACIES, 2019-2028 (IN $ MILLION)

FIGURE 14: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY RETAIL PHARMACIES, 2019-2028 (IN $ MILLION)

FIGURE 15: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY E-COMMERCE, 2019-2028 (IN $ MILLION)

FIGURE 16: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY END-USER, IN 2019

FIGURE 17: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY HOSPITALS & CLINICS, 2019-2028 (IN $ MILLION)

FIGURE 18: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY HOMECARE, 2019-2028 (IN $ MILLION)

FIGURE 19: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY PRODUCT, IN 2019

FIGURE 20: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY METERED DOSE INHALERS, 2019-2028 (IN $ MILLION)

FIGURE 21: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY DRY POWDER INHALERS, 2019-2028 (IN $ MILLION)

FIGURE 22: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY NEBULIZER, 2019-2028 (IN $ MILLION)

FIGURE 23: GLOBAL NEBULIZER MARKET, BY PNEUMATIC NEBULIZER, 2019-2028 (IN $ MILLION)

FIGURE 24: GLOBAL PNEUMATIC NEBULIZER MARKET, BY BREATH ACTUATED PNEUMATIC NEBULIZER, 2019-2028 (IN $ MILLION)

FIGURE 25: GLOBAL PNEUMATIC NEBULIZER MARKET, BY VENTED PNEUMATIC NEBULIZER, 2019-2028 (IN $ MILLION)

FIGURE 26: GLOBAL NEBULIZER MARKET, BY MESH NEBULIZER, 2019-2028 (IN $ MILLION)

FIGURE 27: GLOBAL MESH NEBULIZER MARKET, BY VIBRATING MESH NEBULIZER, 2019-2028 (IN $ MILLION)

FIGURE 28: GLOBAL MESH NEBULIZER MARKET, BY STATIC MESH NEBULIZER, 2019-2028 (IN $ MILLION)

FIGURE 29: GLOBAL NEBULIZER MARKET, BY ULTRASONIC NEBULIZER, 2019-2028 (IN $ MILLION)

FIGURE 30: GLOBAL PULMONARY DRUG DELIVERY MARKET, BY ACCESSORIES, 2019-2028 (IN $ MILLION)

FIGURE 31: NORTH AMERICA PULMONARY DRUG DELIVERY MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

FIGURE 32: THE UNITED STATES PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

FIGURE 33: CANADA PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

FIGURE 34: EUROPE PULMONARY DRUG DELIVERY MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

FIGURE 35: GERMANY PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

FIGURE 36: THE UNITED KINGDOM PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

FIGURE 37: FRANCE PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

FIGURE 38: ITALY PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

FIGURE 39: RUSSIA PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

FIGURE 40: BELGIUM PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

FIGURE 41: POLAND PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

FIGURE 42: REST OF EUROPE PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

FIGURE 43: ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)

FIGURE 44: CHINA PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

FIGURE 45: JAPAN PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

FIGURE 46: INDIA PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

FIGURE 47: AUSTRALIA & NEW ZEALAND PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

FIGURE 48: SOUTH KOREA PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

FIGURE 49: THAILAND PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

FIGURE 50: INDONESIA PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

FIGURE 51: VIETNAM PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

FIGURE 52: REST OF ASIA PACIFIC PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

FIGURE 53: REST OF WORLD PULMONARY DRUG DELIVERY MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)

FIGURE 54: LATIN AMERICA PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

FIGURE 55: MIDDLE EAST & AFRICA PULMONARY DRUG DELIVERY MARKET, 2019-2028 (IN $ MILLION)

  1. MARKET BY APPLICATION
    • ASTHMA
    • CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    • ALLERGIC RHINITIS
    • CYSTIC FIBROSIS
    • OTHER APPLICATIONS
  2. MARKET BY DISTRIBUTION CHANNEL
    • HOSPITAL PHARMACIES
    • RETAIL PHARMACIES
    • E-COMMERCE
  3. MARKET BY END-USER
    • HOSPITALS & CLINICS
    • HOMECARE
  4. MARKET BY PRODUCT
    • METERED DOSE INHALERS
    • DRY POWDER INHALERS
    •    NEBULIZER
      •    PNEUMATIC NEBULIZER
        • BREATH ACTUATED PNEUMATIC NEBULIZER
        • VENTED PNEUMATIC NEBULIZER
      •    MESH NEBULIZER
        • VIBRATING MESH NEBULIZER
        • STATIC MESH NEBULIZER
      • ULTRASONIC NEBULIZER
    • ACCESSORIES
  5. GEOGRAPHICAL ANALYSIS
    •    NORTH AMERICA
      • THE UNITED STATES
      • CANADA
    •    EUROPE
      • GERMANY
      • THE UNITED KINGDOM
      • FRANCE
      • ITALY
      • RUSSIA
      • BELGIUM
      • POLAND
      • REST OF EUROPE
    •    ASIA PACIFIC
      • CHINA
      • JAPAN
      • INDIA
      • AUSTRALIA & NEW ZEALAND
      • SOUTH KOREA
      • THAILAND
      • INDONESIA
      • VIETNAM
      • REST OF ASIA PACIFIC
    •    REST OF WORLD
      • LATIN AMERICA
      • MIDDLE EAST & AFRICA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

Choose License Type

Buy Now